PLYMOUTH MEETING, PA, September 22, 2022 — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
The Patients at the Heart program, which launched in 2019, underscores Harmony’s ongoing commitment to support the comprehensive needs of people affected by rare neurological diseases. Over the last four years, the program has awarded numerous nonprofit organizations that are working to support and address the challenges of people living with sleep disorders and rare neurological diseases who experience excessive daytime sleepiness (EDS).
In 2021, Harmony initiated the Progress at the Heart program. This award funds innovative programs that address health disparities and inequities in rare neurological disease and sleep disorder communities. Combined with the Patients at the Heart awards, total funding for these two programs has now increased to $380,000 in over the last four years.
“Combining empathy with innovation to improve the lives of people living with rare neurological diseases is a mission that drives everyone at Harmony Biosciences,” said Cate McCanless, Chief Corporate Affairs Officer. “In recognition of World Narcolepsy Day, we are pleased to announce this year’s recipients of the Patients at the Heart and Progress at the Heart award programs. This diverse group of organizations have each developed new and innovative patient-centric initiatives to help address the unique needs of people living with rare neurological diseases. We look forward to the positive impact these programs will create for patients, caregivers and communities.”
The following organizations were chosen as the 2022 Patients at the Heart award recipients:
Muscular Dystrophy Association: MDA Access Workshops: Access to Coverage
MDA Access Workshops are a self-paced community learning and support series focused on increasing community health literacy, empowerment, and self-advocacy. The funding will allow for the expansion of MDA Access Workshops and the addition of a new program, Access to Coverage, that will provide an overview of obtaining insurance coverage for medical equipment and assistive devices.
Hypersomnia Foundation: #UNITE Beyond Sleepy – An Interactive Forum for Peer-to-Peer Relational Connections
Establishing the #UNITE program to foster peer-to-peer support for individuals with hypersomnia disorders to connect and share personal challenges.
KLS Foundation: Strategic Communications for Awareness
Increasing outreach and communication with the Kleine-Levin Syndrome community to raise awareness of the condition, build community and support systems, and facilitate initial patient participation in medical studies. The group aims to complete these goals through the development of resources and support opportunities, website and social media updates, and improvements of their patient registry.
Prader-Willi Syndrome Association | USA: Caregiver Retreat
This event will offer up to thirty parents/caregivers an opportunity to attend a three-day, two-night event providing parents/caregivers with new skills to provide care for their loved one with Prader-Willi syndrome and develop their own self-care practices, including meaningful in-person peer connections.
Providing people living with narcolepsy or idiopathic hypersomnia six months of education in the form of webinars and forums in service to PWN4PWN’s advocacy mission.
The following organizations and programs were chosen as the 2022 Progress at the Heart award recipients:
World Sleep Society: Ensuring Equity in the International Sleep Medicine Exam – An Inclusionary Imperative
The World Sleep Society Sleep Medicine Examination is designed to cover many aspects of sleep science, extant practice guidelines, diagnostic nosology, presentation and associated features of sleep disorders, epidemiology of sleep disorders, clinical pharmacology, behavioral therapeutics, instrumentation, methodology, and sleep health. This funding will increase global access to the International Sleep Medicine Examination through the creation of an online testing platform and scholarships for application fees.
Sleep Consortium: Disparity Task Force Initiative – An Inclusive Approach to Patient- Owned Data Collection
This initiative will create a Task Force comprised of individuals representing Black and Hispanic American communities diagnosed with various sleep disorders. The Task Force will concentrate on identifying barriers their communities face in collecting data in patient-owned platforms, consenting to data sharing practices, and understanding governance issues.
Columbia University, Division of Cardiology: “REST: Reinforcing Essentials of Sleep for Teens” in a Diverse Population of High School Students in New York City
A 12-week behavioral and educational program for high school students in the Washington Heights community of New York City that aims to raise awareness of the importance of healthy sleep for the prevention of cardiovascular disease and other chronic diseases.
American Academy of Neurology (AAN) Institute: Diversity Leadership Program
Diversity in the workforce is critical to cultivating trust in underrepresented communities. The Diversity Leadership Program is an intensive program that identifies, orients, and cultivates underrepresented minority neurologists into future leaders of the American Academy of Neurology and the greater field of neurology and helps to increase access to minority neurologists in communities where there is limited representation.
Harmony’s Patients at the Heart award program supports nonprofit organizations. To receive funding, applications must focus on one or more of the following categories:
Harmony’s Progress at the Heart award program supports nonprofit organizations. To receive funding, applications must focus on one or more of the following categories:
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Media Contact:
Harmony Biosciences Investor Contact:
Luis Sanay, CFA